- Home
- WYY vs NRXS Comparison
WYY vs NRXS Comparison
Compare WYY & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WYY | NRXS |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 78.9M |
| IPO Year | 2005 | 2023 |
Fundamental Metrics
Financial Performance| Metric | WYY | NRXS |
|---|---|---|
| Price | $4.65 | $6.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.67 | ★ $13.00 |
| AVG Volume (30 Days) | 29.1K | ★ 213.3K |
| Earning Date | 03-25-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,545,364.00 | $3,569,282.00 |
| Revenue This Year | $5.20 | $142.91 |
| Revenue Next Year | $15.39 | $120.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.59 | ★ 32.89 |
| 52 Week Low | $2.19 | $1.33 |
| 52 Week High | $7.55 | $7.97 |
Technical Indicators
Market Signals| Indicator | WYY | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 51.68 |
| Support Level | $4.13 | $5.77 |
| Resistance Level | $4.99 | $7.97 |
| Average True Range (ATR) | 0.41 | 0.68 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 13.42 | 25.91 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).